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Plasmablastic lymphoma (PBL) is recognized by the World Health Organization as a very aggressive subtype
of non-Hodgkin lymphoma. It was initially described in the setting of human immunodeﬁciency virus (HIV)
infection, but it has since been identiﬁed in immunocompetent patients, as well. PBL is characterized by CD20
negativity and is associated with Epstein-Barr virus infection. The outcome with available therapy is poor,
with median survival of less than 1 year. Multiple adverse prognostic factors have been identiﬁed, including
HIV-negativity, MYC gene rearrangement, high-risk international prognostic index, and not achieving com-
plete remission after induction therapy. The role of intensiﬁcation of induction chemotherapy is controversial.
Novel agents have shown some activity in relapsed setting and may have a role in upfront line of treatment.
The outcome for relapsed PBL is dismal. Autologous hematopoietic cell transplantation (AHCT) appears to be
feasible and may produce better results than chemotherapy, but deﬁnitive data are sparse. Chemosensitivity
before transplantation might be required to beneﬁt from such therapy. Some data suggest a better outcome of
PBL if consolidation with AHCT is used in ﬁrst-line setting, particularly for those with high-risk disease.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Plasmablastic lymphoma (PBL) was ﬁrst described in 1997
by Delecluse and colleagues [1]. In this report, 16 patients, of
whom 15 were infected with human immunodeﬁciency
virus (HIV), presented with an oral mass and aggressive
clinical behavior, poor response to conventional therapies,
and short survival. PBL is now recognized by the World
Health Organization as 1 of the lymphomas that is more
commonly seen in patients with HIV infection [2].
PBL seems to account for 2% to 3% of all HIV-associated
lymphomas, although the actual incidence in HIV-positive,
as well as in HIV-negative, patients is unknown. In HIV-
negative patients, one third of patients have an underlying
immunosuppressive status, such as postesolid-organ or
allogeneic hematopoietic cell transplantation (AlloHCT) [3],
whereas other HIV-negative patients with PBL appear to be
immunocompetent. Based on a literature review, there
seems to be a male predominance (4:1 in HIV-positive anddgments on page 1883.
quests: Monzr M. Al-Malki, Division of
, Roger Williams Medical Center, Boston
vidence, RI 02906.
chartercare.org (M.M. Al-Malki).
2014 American Society for Blood and Marrow
14.06.0091.6:1 in HIV-negative individuals), with younger age at pre-
sentation in HIV-positive (median, 39 years) compared with
HIV-negative individuals (median, 58 years) [4].
Pathologically, PBL is characterized by a monomorphic
proliferation of large, round- to oval-shaped cells with abun-
dant cytoplasm, eccentric nucleus, and prominent nucleolus.
The background is composed of lymphocytes, apoptotic and
mitotic ﬁgures, and macrophages that impart a “starry-sky
appearance” [2]. PBL cells show a plasmacytic immunophe-
notype, in which classic B cell markers, such as CD20, CD79a,
and PAX-5, are lost. However, plasma cell markers, such as
CD38, CD138, and MUM1/IRF4, are expressed [2]. The cell of
origin appears to be the plasmablast, a blastic proliferating
B cell that has switched its phenotype to plasma cells (ie,
activated, nongerminal center B cell) [2]. More recently, novel
immunohistochemistry stains for PRDM1/BLIMP1 and XBP1
have been proposed for the identiﬁcation of PBL [5]. It is of
interest, however, that despite having an immunophenotype
that resembles plasma cells, PBL has a genomic proﬁle closer
to diffuse large B cell lymphoma (DLBCL), regardless of HIV
status [6]. A more recent study published in abstract form
has shown repression of several components of the B cell
receptor-signaling pathway, with similarities between PBL
and extraosseous isolated plasmacytomas when comparedTransplantation.
M.M. Al-Malki et al. / Biol Blood Marrow Transplant 20 (2014) 1877e18841878with DLBCL [7]. These disparate results likely reﬂect an
inherent heterogeneity within PBL.
PBL has been associated with Epstein-Barr virus (EBV)
infection, as EBV-encoded RNA can be detected using an in situ
hybridization technique in the PBL cells in 80% of HIV-positive
and 46% of HIV-negative patients [4]. More recently,MYC gene
rearrangements have been identiﬁed in 40% to 50% of patients
with PBL and appear to confer a worse prognosis [8,9]. The
mechanisms behind the development of MYC gene rear-
rangement in PBL have not been elucidated, as other lym-
phomas associated with MYC gene rearrangements, such as
Burkitt lymphoma and double-hit lymphomas, typically show
a germinal center B cell proﬁle [10,11]. Finally, PBL must be
differentiated from other CD20-negative lymphoproliferative
disorders, such as plasmablastic myeloma, anaplastic lym-
phomakinaseepositiveDLBCL, plasmablasticmicrolymphoma
arising from human herpesvirus 8epositive multicentric
Castleman’s disease, and primary effusion lymphoma [12].
Selected features of PBL and differential diagnoses are shown
in Table 1.
Clinically, PBL presents with advanced clinical stage in
approximately 60% of the patients, regardless of HIV status.
The oral cavity, however, seems to be involved in a higher
proportion of patients with HIV infection [4]. PBL has pre-
dilection for extranodal disease in the gastrointestinal tract,
bone, or skin. PBL can also present in sanctuary sites, such as
the central nervous system or testicles, and 30% of patients
have bone marrow involvement at the time of diagnosis.
PBL is characterized by poor outcomes. In a retrospective
study including 51 HIV-positive PBL patients, the median
progression-free (PFS) and overall survival (OS) were 6 and
11 months, respectively, regardless of intensity of therapy
[13]. In a univariate analysis, factors affecting survival were
achieving complete remission (CR), performance status,
clinical stage, MYC gene rearrangements, and International
Prognostic Index. A German study also identiﬁed short sur-
vival (median OS of 4 months) in patients with HIV-
associated PBL [14]. More recent studies have reported
higher response rates and longer OS in PBL patients [15-17].
Outcome data on HIV-negative patients are sparse. A litera-
ture review showed a median OS of 9 months; CR after in-
duction chemotherapy was the only factor associated with
improved outcomes [3]. Another review showed that HIV-
negative but immunosuppressed PBL patients had a worse
outcome than immunocompetent PBL patients [18].
NONTRANSPLANTATION THERAPEUTIC OPTIONS
The optimal treatment of PBL has not been identiﬁed.
Attempts at curative therapy are often complicated by chal-
lenges associated with delivering chemotherapy to immu-
nocompromised patients. Given that immunocompetentTable 1
Differential Diagnosis of PBL
Diagnosis DLBCL PBL
Association with HIV þþ þþþ
Immunocompetent patients þþþ þ/
CD20 expression þ 
Plasma cell markers þ/ þ
Ki67 expression Intermediate High
Association with EBV 5-15% 80%
Association with HHV8  
Other Oral cavity
PEL indicates primary effusion lymphoma; ALK, anaplastic lymphoma kinase; HHV
B cell lymphoma; PCM, plasma cell myeloma; KS, Kaposi sarcoma; MCD, multicentr
lytic lesions.patients may also have PBL, approaches must be highly
customized for individual patients. Prospective studies to
deﬁne a standard of care are lacking. The majority of what is
known about treating this aggressive neoplasm comes from
case reports and retrospective case series. The most relevant
of these are reviewed here.
Because PBLs are nearly always CD20-negative, there is no
role for anti-CD20 monoclonal antibody therapy. Multiagent
chemotherapy is typically attempted as ﬁrst-line therapy. A
10-year retrospective review by the AIDS Malignancy Con-
sortium of 19 newly diagnosed PBL patients treated with a
variety of regimens, including CHOP (cyclophosphamide,
hydroxydaunorubicin, vincristine, and prednisone), showed a
1-year survival of 67% [15]. AlthoughCHOP is oftengiven, there
is a suggestion that more aggressive therapy leads to better
outcomes. For example, Barta et al. presented apooled analysis
of 1546 patientswithHIV-associated non-Hodgkin lymphoma
(NHL), demonstrating improved OS with infusional EPOCH
(etoposide, prednisone, vincristine, doxorubicin, cyclophos-
phamide) [19]. PBL, identiﬁed only as “other histology” in this
paper, constituted only 6% of the patients [19].
In the largest case series of HIV-positive PBL, the majority
of patients received CHOP, whereas 37% were given more
intensive regimens, such as EPOCH [13]. Although the com-
plete response rate was 66%, the majority of patients
relapsed and ultimately died of their disease. Themedian PFS
was 6 months and median OS was 11 months [13]. In this
case series and another review [20], the use of regimens
more intensive than CHOP did not provide apparent PFS or
OS beneﬁts.
Nevertheless, the preference for more aggressive therapy
has been advocated by the National Comprehensive Cancer
Network guidelines, which state, “standard CHOP is not
adequate therapy.” The National Comprehensive Cancer
Network suggests modiﬁed CODOX-M/IVAC (cyclophospha-
mide, vincristine, doxorubicin, methotrexate/ifosfamide,
etoposide, cytarabine), dose-adjusted EPOCH, or HyperCVAD
(hyperfractionated cyclophosphamide, vincristine, doxoru-
bicin, dexamethasone alternating with methotrexate and
cytarabine) as primary therapy. The evidence supporting
these recommendations arises from single-center case series
[21]. TheMDAnderson group has demonstrated a 38% 5-year
OS in PBL patients; approximately one half received Hyper-
CVAD [16]. Given the well-established record of dose-
adjusted EPOCH in HIV-associated NHL, this has become
the ﬁrst-line treatment of choice for most clinicians [22,23].
A phase II clinical trial (CTSU 9177) by the Southwest
Oncology Group is attempting to study this regimen in a
prospective manner in the setting of HIV-related NHL [24].
Relapsed disease is highly problematic. From AIDS Ma-
lignancy Consortium data, Noy et al. reported that long-termPEL ALKþ DLBCL HHV8þ LBCL PCM
þþþ  þ 
þ/ þ þ/ þþ
þ/  þ/ 
þ þ þ þ
High High High Low
90%   
100%  100% 
Effusions ALKþ KS, MCD CRAB
8, human herpesvirus 8; DLBCL, Diffuse large B cell lymphoma; LBCL, large
ic Castleman disease; CRAB, hypercalcemia, anemia, renal dysfunction, bone
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M.M. Al-Malki et al. / Biol Blood Marrow Transplant 20 (2014) 1877e1884 1879survival in patients with relapsed or refractory disease is
possible but rare [15]. Autologous hematopoietic cell trans-
plantation (AHCT) is felt to offer the best chance of cure and
should be pursued in patients with chemosensitive disease
who are candidates for high-dose therapy. Bortezomib is a
proteasome inhibitor with activity in multiple myeloma and
certain subtypes of NHL. There is growing evidence that it is
an active agent in relapsed PBL. Several case reports describe
prompt responses to bortezomib, even in highly refractory
patients [25-28]. Bortezomib has been safely combined
with rituximab, cyclophosphamide, hydroxydaunorubicin,
vincristine, and prednisone (R-CHOP) in clinical trials for
speciﬁc subtypes of DLBCL [29] and may be an appealing
choice for development in PBL. CD30 expression can be
found in approximately 30% of PBL [30-32]. A case report
showed that the anti-CD30 antibody-drug conjugate bren-
tuximab vedotin can have activity against PBL [33], and may
be a reasonable option for patients with CD30-positive
relapsed PBL who are not suitable for more aggressive
therapy.
TRANSPLANTATION THERAPEUTIC OPTIONS
The PARMA trial made high-dose antitumor chemo-
therapy and AHCT the standard of care for relapsed chemo-
sensitive HIV-negative NHL [34]. Several other randomized
trials have corroborated this ﬁnding [35,36]. Moreover, AHCT
has been used to consolidate initial therapy in patients with
poor prognostic features CR1 [37-39]. Recently, after the
introduction of combination antiretroviral therapy (cART),
the role of AHCT in HIV-positive patients with NHL has been
entertained and has been shown to be feasible [40-45]. No
randomized trials have been reported or conducted in the
setting of PBL, and none are likely to be conducted because of
the rarity of the disease and the heterogeneity of treatment.
Most of the data have been extrapolated from larger phase II
trials, retrospective analysis of individual center’s experi-
ence, or case reports of subtype of DLBCL.
A preliminary data report from the center for Interna-
tional Blood and Marrow Transplant Research (CIBMTR) in-
dicates 20 patients who received a ﬁrst AHCT for PBL in CR1
or CR2 between 2001 and 2012 are registered with the
CIBMTR. HIV status was not reported. Median age at trans-
plantation was 55 (range, 32 to 76). Eleven of 20 (55%) pa-
tients underwent transplantation in CR1. Relapse data were
not reported, but 1-year and 3-year OS rates were 69% (95%
conﬁdence interval [CI], 48% to 87%) and 45% (95% CI, 21% to
71%), respectively. (CIBMTR unpublished data)
AHCT IN REFRACTORY OR RELAPSED PBL
HIV-positive Patients with PBL
In refractory or relapsed HIV-related lymphoma in gen-
eral, including HIV-positive patients with PBL, treatment was
considered mainly palliative with some rare cases of long-
term survival. Median survival of patients with HIV-related
lymphoma in the pre-cART era was 2.1 months in 1 Italian
cohort [46], but better results have been reported since the
inclusion of cART into treatment regimens [47-49]. In a
retrospective analysis of 70 chemotherapy-treated HIV-pos-
itive patients with PBL between 1997 and 2009, the median
OS for patients with refractory disease was 3.5 months [20].
Although the use of cART in HIV-positive patients with
PBL did not seem to confer a survival advantage in 1 study
[13], another retrospective analysis [20] showed a statistical
trend towards improved survival. In the Italian cooperative
group’s experience [17], there was a trend towards a better
Table 3
Main Characteristics of Patients with Relapsed/Refractory PBL Who Underwent Transplantation within GICAT and Updated Outcome
Patient
No. [Ref]
Age, yr Gender Stage at
Relapse
Induction/Salvage
Chemotherapy
Disease Status
at ASCT
Conditioning Response
after ASCT
Survival after
ASCT, mo
1 [58] 43 M IV A CHOP14 (RD) ESHAP PR BEAM CR 79þ
2 [58] 53 M IV A CHOP21/IEV PR BEAM PR 6 (died, PD)
3 [58] 36 M IV A R-CDE*/ESHAP RD BEAM RD 4 (died, PD)
4 [17] 30 M IV A CHOP21/ESHAP PR BEAM CR 36þ
5 [17] 47 M IV A CHOP14/ESHAP PR BEAM CR 21þ
ESHAP indicates etoposide, methylprednisolone, high-dose cytarabine, and cisplatin; IEV, ifosphamide, epirubicin, and etoposide; PD, progressive disease;
R-CDE, rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide; RD, refractory disease.
* Treated upfront with rituximab with CD20 positive disease.
M.M. Al-Malki et al. / Biol Blood Marrow Transplant 20 (2014) 1877e18841880prognosis in patients with PBL in the post-cART era as well
(3-year OS 25% versus 83%, P ¼ .056). In addition to that, CR
has been reported in some cases after starting cART [50].
Furthermore, many relapses have been reported in PBL pa-
tients who stopped cART [20,51,52]. Now, intensive chemo-
therapy [53,54] and AHCT [40-45] are feasible treatment
modalities with comparable results to matched HIV-negative
patients [43,55].
Multiple experiences with AHCT in HIV-positive patients
with lymphoma from single centers or cooperative group
have been published (Table 2). All have shown the feasibility
and safety of the procedurewith treatment-relatedmortality
(TRM) in the range of 5% to 10%. In 2 separate matched case
control analyses, HIV status did not inﬂuence the outcome of
AHCT in patients with NHL [43,55]. Although the opportu-
nistic infections rate was somewhat higher in the HIV-
positive group, it did not affect TRM. In almost all patients
included in both analyses, cART was continued throughout
the procedure, except for short interruptions. Furthermore,
immune recovery after AHCT for HIV-related NHL is similar
to that observed in HIV-negative patients [56,57].
The effectiveness of such therapy (ie, DFS and OS) was not
signiﬁcantly different between HIV-positive and HIV-
negative group of patients [43,55]. In the Italian Coopera-
tive Group on AIDS and Tumors (GICAT) study [58], the
median OS of patients who did not proceed to AHCT ac-
cording to study protocol (either due to chemoresistant
disease, progression of disease before transplantation, or
mobilization failure) was 7 months with a 3-year PFS of 13%,
compared with 76% for patients who received a transplant
(P < .001, log-rank test), but this may be because of selection
bias. On the other hand, the low relapse rate (12% to 15%) and
the plateau in PFS 12 to 18 months after transplantation in
multiple reports are encouraging [39,40,58]. However, the
small number of patients, and, in particular, PBL patients
(Table 3), precludes any ﬁrm conclusions.Table 4
Case Reports of Relapsed HIV-Positive Patients with PBL and Their Reported Outco
Patient
No. [Ref]
Age, yr Gender
(M/F)
Stage aaIPI CD4 Count before
ASCT Cell/micL
Induction
Regimen/
Salvage Tx
1 [21] 36 M IV 4 167 CHOP X8
PD: DHAP
2 [51] 36 M IE 1 192 (on diagnosis) CHOP
PD: IVAC
3 [52] 51 M IE 2 100 CHOP/RT
PD: mESHAP
and ICE
Tx indicates treatment; DHAP, dexamethasone, high-dose cytarabine, and cisplatin
cytarabine; RT, radiation; mESHAP, modiﬁed etoposide, methylprednisolone, high
MEAM, MCNU, etoposide, cytarabine, and melphalan.
R-CHOP: rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and preIn a registry-based analysis from the European Group for
Blood and Marrow Transplantation (EBMT), 8% of patients
with NHL had PBL [59]. Age older than 50 years was associ-
ated with higher TRM. On the other hand, histology consis-
tent with PBL, delayed referral to AHCT, and not being in CR
at the time AHCT were associated with higher risk of disease
relapse.
Some case reports have been presented in the literature
describing cases of HIV-positive patients with PBL, in
particular with mixed results (Table 4). In 1 case report [51],
authors suggested that demonstration of an IgH/MYC fusion,
which was shown in multiple retrospective analyses to
confer poor prognosis in PBL [8,13,20], might account for the
rapid proliferation, aggressive clinical course, and poor
outcome despite the use of AHCT in relapse settings. It was
postulated that AHCT earlier in the course of disease might
have overcome this adverse feature.
HIV-negative Patients with PBL
The Mofﬁtt Cancer Center presented a single-institution
experience on 9 consecutive HIV-negative patients diag-
nosed with PBL between 1999 and 2010 [18]. The median age
at diagnosis was 58 years (range, 46 to 67 years). Five of 9
patients (55%) had an age-adjusted International Prognostic
Index (aaIPI)  2. Seven of 9 (78%) patients received CHOP.
Four of them received rituximab, 1 patient for EBV-
reactivation after AlloHCT, and 3 others for no reported
reason. Two of 9 patients (22%) were treated with Hyper-
CVAD regimen. Seven (78%) patients achieved CR with
chemotherapy. One patient had partial response adequate
for AHCT consolidation and 1 required additional therapy.
The overall response rate was 89%. Four patients (44%) with
an aaIPI  2 underwent AHCT after achieving CR1 (Table 5).
The median OS was not reached at the time of report.
Authors of this article also presented a literature review
on 70 HIV-negative PBL patients [18]. Sixty percent ofme in Literature
Disease Status
before ASCT
Conditioning
Regimen
Disease Status
after ASCT
Outcome OS at Last
Follow-up, mo
CR2 BCNU/CY CR A-NED 25
PR2 CBV CR PD 4 mo 14
PR2 MEAM CR A-NED 16
; A-NED, alive with no evidence of disease; IVAC, ifosfamide, etoposide, and
-dose cytarabine, and cisplatin; ICE, ifosfamide, carboplatin, and etoposide;
dnisone.
Table 5
Case Reports of HIV-Negative Patients with PBL and Their Reported Outcome in Literature
Patient
No. [Ref]
Age,
yr
Gender
(M/F)
Stage Immune Status aaIPI Induction Regimen Disease
Status
before AHCT
Conditioning
Regimen
Disease
Status
after AHCT
DFS after
AHCT, mo
OS at Last
follow-up, mo
1 [18,21] 23 M IV Competent 2 HyperCVAD  2
PD: IVAC  3
PR2 BEAM CR 5 12 (died)
2 [18,75] 57 M IV Cardiac
transplant
(cyclosporine)
2 Cyclosporine w/d
Cy/MTX
PD: ICE  3
PR2 Chemo-based PD PD 6 (died)
3 [18] 63 F IV Competent 5 HyperCVAD  4 CR1 BEAM CR 2 13.3 (died)
4 [18] 60 F IV Competent 3 HyperCVAD  4 PR1 BEAM CR 14 36.5 (died)
5 [18] 64 M IIE Competent 2 R-CHOP  6 CR1 BEAM CR A-NED 25.3
6 [18] 67 M IV Competent 3 CHOP  1
R-CHOP  5
CR1 BEAM CR A-NED 46.7
7 [60] 36 M IV Competent 2 ProMACE/CytaBOM CR1 BEAM CR NR 16.9 (died)
8 [60] 52 F II Competent 1 CHOP  6
PD: MiniBEAM
PR2 Cy-TBI CR 2.5 17.2 (died)
9 [60] 50 M II Competent 0 CHOP: RD
MiniBEAM: RD
ICE
RD/CR1 BEAM PD PD 14 (died)
W/d indicates withdrawal; MTX, methotrexate; R-CHOP, rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone; ProMACE/CytaBOM,
cyclophosphamide, doxorubicin, etoposide cytozar, bleomycin, vincristine, methotrexate and prednisone.
M.M. Al-Malki et al. / Biol Blood Marrow Transplant 20 (2014) 1877e1884 1881patients were treated with CHOP or a CHOP-like regimen.
Two patients with primary refractory disease (Table 5)
received AHCTand survived 6 and 12months. Themedian OS
was 9 months. The authors concluded that age, extranodal
disease, and immunosuppression were adverse prognostic
features associated with poor outcome. The authors attrib-
uted the improved outcome in their single institutional
experience in comparison with historical data to the upfront
utilization of AHCT in patients with high-risk disease.
Some case reports have been presented in literature
describing the feasibility of AHCT in HIV-negative PBL
(Table 5). In 1 case series [60], association with TP53 gene
deletion and activated B cell phenotype were proposed as
possible mechanisms for PBL chemoresistance and poor
outcome.AHCT CONSOLIDATION IN CR1 FOR HIGH-RISK PBL
Multiple studies have reported that up to 60% of patients
with relapsed or refractory lymphoma in general will prog-
ress before reaching AHCT [34,44,58,61]. Furthermore, the
outcome of patients with relapsed or refractory PBL is very
poor [12,13,20]. Because the outcome is signiﬁcantly superior
in patients with relapsed NHL who received AHCT compared
with those who did not [35-37,58], it seems rational to
explore the use of AHCT earlier in the course of disease, at
least in the subgroup of patients with high-risk disease.
In an EBMT registry study [59], some NHL histologies (eg,
plasmablastic) have increased risk of relapse compared with
DLBCL (relative risk, 3.4; 95% CI, 1.1 to 10.4; P ¼ .03) and
possible tendency for poorer survival. It was suggested that
AHCT in CR1 could be of beneﬁt to this subset of patients.
Another study showed poor clinical outcome of patients with
relapsed PBL histology compared with standard DLBCL his-
tologies (centroblastic and immunoblastic) even to AHCT in
CR2 (median OS of 14 months compared with not reached,
with 5-year survival of 57% in other histologies, P ¼ .002)
[60]. Moreover, the International Prognostic Index has been
reported as a useful prognostic factor in patients with HIV-
positive and HIV-negative lymphoma [62-64], and spe-
ciﬁcally for PBL, as well [13]. Furthermore, in previous
investigational experiences, an aaIPI more than 1 or 2 (in
some trials) has been used as an eligibility criterion forconsolidation therapy with AHCT for patients in both groups
in CR1 [39,42,61,65].
GICAT presented an interim analysis of a phase II multi-
center trial of early consolidation with AHCT in HIV-positive
patients with NHL [66] and later published their experience
speciﬁcally in HIV-positive patients with PBL [17]. Twenty
newly diagnosed HIV-positive patients with aggressive NHL
and an aa-IPI of 2 or 3 were enrolled in this study between
2007 and 2012. The induction therapy used in this protocol
was CHOP  rituximab. Peripheral stem cell collection with
high-dose cyclophosphamide and granulocyte colonye-
stimulating factor was initiated when chemosensitivity was
conﬁrmed. All patients received cART during the entire
treatment program. At the time of presentation, 10 patients
of the entire group underwent AHCT. The procedurewas well
tolerated; there were no transplantation-related deaths. All
patients who underwent transplantation were alive and free
of progression after a median follow-up of 43 months (range,
4 to 58 months). Four patients in this study had PBL [66,17].
One patient had prolonged cytopenia during induction
therapy and was excluded from study (she is still in CR1
at þ34 months). The other 3 patients received trans-
plantation with BEAM (BCNU, etoposide, cytarabine,
melphalan) conditioning regimen in CR1, as planned after
induction therapy. All of them are alive and in remission
at þ24, þ19, and þ13 months (Table 6). In the entire series,
with a median follow-up of 19.5 months (range, 4 to 65), the
2-year PFS and OS were 73% and 76%, respectively (Figures 1
and 2).
Two additional HIV-positive patients with high-risk PBL
were treated with AHCT as upfront consolidation after in-
duction with CHOP in a GICAT center in Italy, and the results
were reported separately [17]. One patient is still alive in CR
at þ83 months, but the other progressed and died 4 months
after transplantation (Table 6).
Comparable to the Italian cooperative group’s and the
Mofﬁtt Cancer Center’s experiences, patients with PBL
registered with the CIBMTR were stratiﬁed by disease status;
7 of 11 (64%) patients who underwent AHCT in CR1 were
alive at most recent follow-up, with a median follow-up of
25 months (range, 4 to 43 months) compared with 4 of 9
(44%) patients who underwent AHCT in CR2 after a median
follow-up of 62 months (range, 12 to 104 months). (CIBMTR
Table 6
Main Characteristics of Patients with PBL and aaIPI of Two or Greater Who Underwent Transplantation in CR1 from GICAT and Their Updated Outcome
Patient No. [Ref] Age, yr Gender Stage Disease Status
at ASCT
Induction
Chemotherapy
Conditioning Response
after ASCT
Survival after
ASCT, mo
1 [17] 36 M IV A CR1 CHOP-21 BEAM CR 83þ
2 [66] 46 M IV A CR1 CHOP-14 BEAM CR 24þ
3 [66] 38 M IV A CR1 CHOP-14 BEAM CR 19þ
4 [66] 54 M IV A CR1 CHOP-14 BEAM CR 13þ
5 [17] 35 M IV B CR1 CHOP-14 BEAM PD 4 (died)
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small to draw any statistical conclusion.
Ideally, randomized studiesmust be conducted to establish
the merit of AHCT in PBL. Until then, and based on the avail-
able data, we propose that PBL patients with the following
high-risk features should be considered for consolidationwith
AHCT in ﬁrst-line setting: aaIPI score of more than 2, HIV-
negative status, MYC gene rearrangement, TP53 gene dele-
tion, or any response to induction chemotherapy other than
CR (partial response or refractory disease).
ALLOHCT FOR PBL
The literature on AlloHCT in HIV-positive patients with
NHL in general, and PBL in particular, is considerably more
limited compared with AHCT. An early enthusiasm for
AlloHCT in patients with HIV infection was tempered by
several challenges, casting serious doubts about the feasi-
bility of this curative modality in HIV-positive patients with
hematologic malignancies [67-69]. Among those challenges
presented: signiﬁcant exposure to opportunistic infection, a
high incidence of concomitant infections (ie, viral hepatitis),
complex drug-drug interactions between antiretroviral and
transplantation-related medications, and effect of HIV on
Tcell number and function, bonemarrowmicroenvironment,
and cytokine milieu, all reﬂecting not only on increased TRM
but also on mortality related to HIV-infection itself.
In the pre-cARTera, AlloHCTattemptswere unsuccessful in
the setting of HIV-related malignancies [70-72]. A retrospec-
tive study from the EBMT conﬁrmed the negative outcome in
the pre-cART era, but it showed that the introduction of cART
improved the OS of patients undergoing AlloHCT [71]. In a
retrospective study of 23 patients with various hematologic
malignancies from the CIBMTR [72], patients underwent
matched sibling (n ¼ 19) or unrelated donor (n ¼ 4) AlloHCT
between 1987 and 2003. The median age at transplantation
was 32 years (range, 9 to 43 years). Forty-three percent of
patients had NHL. Seventy-eight percent of patients received
bonemarrowstemcells.Mostpatients (87%)were conditionedFigure 1. Survival after transplantation (10 patients).with myeloablative regimens and 70% of patients received
cyclosporine-based graft-versus-host disease (GVHD) pro-
phylaxis with or without methotrexate. Median time to
neutrophil engraftment was 16 days (range, 7 to 30 days).
Engraftment failure ratewas 20%. TRM at 100 dayswas high at
46% and was likely due to regimen-related toxicity (ie, pul-
monary toxicity among patients receiving total body irradia-
tion) and infections. With a median follow-up of 59 months,
the cumulative incidence of grade II to IV acute GVHD, chronic
GVHD, and survival at 2 years were 30% (95% CI, 14% to 50%),
28% (95% CI, 12% to 48%), and 30% (95% CI, 14% to 50%),
respectively. Therewas a difference in survival inpatientswho
underwent transplantation before and after 1996, after avail-
ability of cART. Before 1996, 2 of 14patients (15%) survived, but
after 1996, 4 of 9 patients (45%) survived. This study revealed
that reduction of TRM and control of HIV infection together
are imperative in carrying out successful AlloHCT in this
population.
Because the development of reduced-intensity condi-
tioning regimens has improved the outcomes of AlloHCT in
general due to decrease in TRM, its role in the HIV-positive
patients remains to be deﬁned. The feasibility of the proce-
dure was demonstrated when a 51-year-old HIV-positive
man with PBL and a hematopoietic cell transplant comor-
bidity index of 4 (high risk) underwent AlloHCT from
matched unrelated donor [73]. He was conditioned with
ﬂudarabine, busulfan, and antithymocyte globulin. GVHD
prophylaxis included methotrexate and tacrolimus. He was
alive at the time of report 2 years after transplantation with
no evidence of disease and off immunosuppression. He had
grade II acute GVHD and limited grade chronic GVHD. The
patient was continued on cART throughout the procedure.
His CD4þ count was 472/mL on day 100 after transplantation.
Currently, a formal study of AlloHCT for treatment of
hematologic malignancies in HIV patients by the Blood and
Marrow Clinical Trials Network is recruiting [74].
There has been no report in the literature describing
AlloHCT in HIV-negative PBL patients.Figure 2. Survival from study entry (20 patients).
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PBL is an aggressive and rare subtype of NHL, often
associated with HIV and EBV infections. Results of current
available chemotherapy regimens remain poor. Intensiﬁca-
tion of induction chemotherapy to achieve better results is
controversial. AHCT appears to be feasible and possibly
beneﬁcial compared with multiagent chemotherapy in the
setting of relapsed and refractory disease. With the dismal
outcome of salvage chemotherapy and with the large num-
ber of patients with progressive disease waiting for trans-
plantation, AHCT in CR1 should be considered, at least in
high-risk patients, in an attempt to improve outcome of
this disease. Prospective clinical trials are needed; some are
ongoing and might help improve our approach to a better
treatment.
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